- Conditions
- SMA - Spinal Muscular Atrophy, Gene Therapy
- Interventions
- Onasemnogene Abeparvovec-xioi
- Biological
- Lead sponsor
- Novartis Gene Therapies
- Industry
- Eligibility
- Up to 180 Days
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 16
- States / cities
- Los Angeles, California • Stanford, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced May 21, 2026, 5:32 PM EDT